TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7534320

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (Norditropin, 4 I.U. twice daily) for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional medical treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Recombinant human growth hormone and Conventional medical treatment
Number of subjects: 20
Study: 3076793

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg sublingually
Number of subjects: 0
Study: 31763933

Group type: EXPERIMENTAL
Intervention: Housing First program
Number of subjects: 418
Study: 30169980

Group type: EXPERIMENTAL
Intervention: Melatonin nanostructured lipid carriers (NLCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Melatonin solution
Number of subjects: 0
Study: 28369269

Group type: EXPERIMENTAL
Intervention: Internet behavioral weight loss program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 26412528

Group type: EXPERIMENTAL
Intervention: Encapsulated Saccharomyces cerevisiae JCM 7255
Number of subjects: 0
Study: 23433639

Group type: EXPERIMENTAL
Intervention: BPRS total score of 18
Number of subjects: 3767

Group type: EXPERIMENTAL
Intervention: BPRS total score of 30
Number of subjects: 3767

Group type: EXPERIMENTAL
Intervention: BPRS total score of 40
Number of subjects: 3767

Group type: EXPERIMENTAL
Intervention: BPRS total score of 50
Number of subjects: 3767

Group type: EXPERIMENTAL
Intervention: BPRS improvement of 10 points
Number of subjects: 3767

Group type: EXPERIMENTAL
Intervention: BPRS improvement of 20 points
Number of subjects: 3767

Group type: EXPERIMENTAL
Intervention: BPRS improvement of 30 points
Number of subjects: 3767

Group type: EXPERIMENTAL
Intervention: BPRS improvement of 40 points
Number of subjects: 3767

Group type: EXPERIMENTAL
Intervention: BPRS percentage improvement of 19% from baseline
Number of subjects: 3767

Group type: EXPERIMENTAL
Intervention: BPRS percentage improvement of 30% from baseline
Number of subjects: 3767

Group type: EXPERIMENTAL
Intervention: BPRS percentage improvement of 40% from baseline
Number of subjects: 3767

Group type: EXPERIMENTAL
Intervention: BPRS percentage improvement of 50% from baseline
Number of subjects: 3767
Study: 21599894

Group type: EXPERIMENTAL
Intervention: Multidisciplinary, evidence-based care program for depression management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Care program
Number of subjects: 0
Study: 18343310

Group type: EXPERIMENTAL
Intervention: Concomitant boost radiotherapy (67.5 Gy/40 fractions over 5 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional radiotherapy (66 Gy in 33 fractions over 6.5 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concomitant boost radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 0
Study: 16839840

Group type: EXPERIMENTAL
Intervention: Insulin infusion after exercise
Number of subjects: 7

Group type: COMPARATOR
Intervention: Insulin infusion at rest
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Insulin infusion in both trials
Number of subjects: 7
Study: 12959745

Group type: EXPERIMENTAL
Intervention: Downregulated isoprenoid pathway with decreased digoxin synthesis in patients with left hemispheric dominance.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased lysosomal stability, elevated ubiquinone levels, and decreased free radical levels in patients with left hemispheric dominance.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperdigoxinemia with an upregulated isoprenoid pathway in patients with right hemispheric dominance.
Number of subjects: 0
Study: 10689885

Group type: EXPERIMENTAL
Intervention: Contrast medium volume of 120 ml
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Contrast medium volume of 2.0 <, < or = 2.5 ml/kg
Number of subjects: 48
Study: 8936543

Group type: EXPERIMENTAL
Intervention: 21 g standard bevelled intramuscular needle
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: 23 g standard bevelled intramuscular needle
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: 22 g short bevelled 'regional block' needle
Number of subjects: 623
Study: 1593248

Group type: EXPERIMENTAL
Intervention: Referral to a specific group cessation program (including a video and waived fees)
Number of subjects: 1380

Group type: COMPARATOR
Intervention: Advice only (control group)
Number of subjects: 1380
Study: 3920862

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 30987551

Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid (ALA) 600 mg daily for 8 weeks
Number of subjects: 63
Study: 30203760

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy combined with radioactive iodine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional total thyroidectomy
Number of subjects: 120
Study: 26802793

Group type: EXPERIMENTAL
Intervention: Replacing usual worry with images of possible positive outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Replacing usual worry with positive outcomes represented verbally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generating positive images not related to worries (control condition)
Number of subjects: 0
Study: 25942341

Group type: EXPERIMENTAL
Intervention: Stem cells in combination with bioresorbable PLA/PGA membrane
Number of subjects: 24

Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 24
Study: 22067774

Group type: EXPERIMENTAL
Intervention: 4% intrauterine lidocaine infusion
Number of subjects: 58

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 58
Study: 18690013

Group type: EXPERIMENTAL
Intervention: Infanrix hexa (GlaxoSmithKline Biologicals; N = 246)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Hexavac (Sanofi Pasteur MSD; N = 248)
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 494
Study: 17167254

Group type: EXPERIMENTAL
Intervention: 20% sucrose solution exposure 2 times/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20% sucrose solution exposure 4 times/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20% sucrose solution exposure 6 times/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20% sucrose solution exposure 8 times/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20% sucrose solution exposure 10 times/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (0 times/day sucrose exposure)
Number of subjects: 10
Study: 15987395

Group type: EXPERIMENTAL
Intervention: Fluid loading with 2 litres of Ringer acetate
Number of subjects: 10

Group type: COMPARATOR
Intervention: No fluid loading
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluid loading
Number of subjects: 10
Study: 12462684

Group type: EXPERIMENTAL
Intervention: Banded Herbst appliance for six months
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cast-silver splinted Herbst appliances for seven months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both appliances
Number of subjects: 28
Study: 10075384

Group type: EXPERIMENTAL
Intervention: Isoflavonoid supplement (55 mg daily including 30 mg genistein, 16 mg biochanin A, 1 mg daidzein, 8 mg formononetin)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Isoflavonoid supplement
Number of subjects: 59
Study: 7719894

Group type: EXPERIMENTAL
Intervention: Turbuhaler inhalation of terbutaline (0.125, 0.25, 0.5, 1.0, 2.0 mg doses)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Pressurized metered dose inhaler inhalation of terbutaline (0.125, 0.25, 0.5, 1.0, 2.0 mg doses)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Turbuhaler and Pressurized metered dose inhaler
Number of subjects: 31
Study: 1827311

Group type: EXPERIMENTAL
Intervention: Spiroplatin at 30 mg/m2 by 4 h infusion every 3 weeks (recommended dose for phase II studies)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Spiroplatin at 35 mg/m2 (MTD for poor-risk patients)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Spiroplatin at 40 mg/m2 (MTD for good-risk patients)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Spiroplatin (dose-dependent)
Number of subjects: 67
Study: 6976947

Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Coltsfoot
Number of subjects: 24
Study: 6705447

Group type: EXPERIMENTAL
Intervention: 2‐mg nicotine gum
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4‐mg nicotine gum
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 12
Study: 31222392

Group type: EXPERIMENTAL
Intervention: Daily symptom reporting with electronic patient-reported outcomes (PROs)
Number of subjects: 76
Study: 30322156

Group type: EXPERIMENTAL
Intervention: Intensive care group (moderate hypocaloric Mediterranean diet and nutritional education)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 107
Study: 26955912

Group type: EXPERIMENTAL
Intervention: Group physiotherapy (GRP)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Individual physiotherapy (IND)
Number of subjects: 34
Study: 25195060

Group type: EXPERIMENTAL
Intervention: Betamethasone (8 mg intravenously before surgery)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no betamethasone)
Number of subjects: 80
Study: 22366106

Group type: EXPERIMENTAL
Intervention: Early ambulation at 4 hours post-cardiac catheterization
Number of subjects: 137

Group type: COMPARATOR
Intervention: Routine post-procedure care of 12 to 24 hours (Control)
Number of subjects: 137
Study: 20615842

Group type: EXPERIMENTAL
Intervention: Shared decision making
Number of subjects: 16
Study: 18689565

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sedentary (SE)
Number of subjects: 36
Study: 15926966

Group type: EXPERIMENTAL
Intervention: CRN team leader and CRNs
Number of subjects: 378

Group type: COMPARATOR
Intervention: CRNs and ward-based nurses
Number of subjects: 378
Study: 11209104

Group type: EXPERIMENTAL
Intervention: Seven week pulmonary rehabilitation programme
Number of subjects: 44

Group type: COMPARATOR
Intervention: Four week pulmonary rehabilitation programme
Number of subjects: 44
Study: 9644112

Group type: EXPERIMENTAL
Intervention: PGE1 infusion (30 micrograms/h for 2-6 h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 24
Study: 7840523

Group type: COMPARATOR
Intervention: Tamoxifen alone (loading dose of 160 mg on the first day)
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant tamoxifen
Number of subjects: 473
Study: 3398697

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP, 30 micrograms/kg/h)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 19
Study: 31920008

Group type: EXPERIMENTAL
Intervention: Gefitinib in EGFR-positive tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy in EGFR-positive tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy in EGFR-negative tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gefitinib in EGFR-negative tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGFR-negative tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EGFR-positive tumors
Number of subjects: 0
Study: 29915988

Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate beverage (400 mL evening before and 400 mL morning before surgery)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo (flavored water, same quantity as carbohydrate beverage)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Fasting from midnight until surgery (Group MN-NPO)
Number of subjects: 153
Study: 27070228

Group type: EXPERIMENTAL
Intervention: WaveLight Allegretto Wave Eye‐Q 400‐Hz excimer laser
Number of subjects: 50

Group type: COMPARATOR
Intervention: VISX Star S4 IR CustomVue excimer laser
Number of subjects: 50
Study: 24797760

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing (DDD-R)
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Ventricular pacing (VVI-R)
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: First-degree AV-block
Number of subjects: 2010

Group type: COMPARATOR
Intervention: Normal PR interval
Number of subjects: 2010
Study: 22375604

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no EPA supplementation)
Number of subjects: 12
Study: 20051525

Group type: EXPERIMENTAL
Intervention: Parenting the Strong-Willed Child (PSWC) book
Number of subjects: 52

Group type: COMPARATOR
Intervention: Touchpoints: Three to Six (comparison book)
Number of subjects: 52
Study: 17698986

Group type: EXPERIMENTAL
Intervention: Ala/Ala(94) mutation
Number of subjects: 1453

Group type: COMPARATOR
Intervention: Wild-type (Thr/Thr(94))
Number of subjects: 1453

Group type: EXPERIMENTAL
Intervention: Lipid/heparin-somatostatin-insulin-glucagon clamps
Number of subjects: 1453

Group type: EXPERIMENTAL
Intervention: Euglycemic-hyperinsulinemic clamps
Number of subjects: 1453
Study: 16222155

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg/day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 12002967

Group type: EXPERIMENTAL
Intervention: Computer-synthesized speech by a disabled speaker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer-synthesized speech by a nondisabled speaker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural speech by a disabled speaker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural speech by a nondisabled speaker
Number of subjects: 0
Study: 10682463

Group type: EXPERIMENTAL
Intervention: Ritodrine 100 mg in 5% glucose 500 ml intravenous, adjusted drip speed starting at 8 drips per minute, oral ritodrine after 12 hours if no contractions or bleeding.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 50
Study: 7699441

Group type: EXPERIMENTAL
Intervention: 201Tl reinjection immediately after stress‐redistribution planar imaging (Group A)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: 201Tl reinjection on a separate day followed by rest‐redistribution imaging (Group B)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Group A
Number of subjects: 402

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 402
Study: 2665305

Group type: EXPERIMENTAL
Intervention: Solcoseryl and film-forming glue 'Statizol'
Number of subjects: 300

Group type: COMPARATOR
Intervention: Routine treatment of ulcers
Number of subjects: 300
Study: 989965

Group type: EXPERIMENTAL
Intervention: Low molecular weight sodium heparin (mean m.w. 9,000)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sodium heparin (m.w. 15,000)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Calcium heparin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High molecular weight sodium heparin (mean m.w. 22,000)
Number of subjects: 6
Study: 29334290

Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream
Number of subjects: 144

Group type: COMPARATOR
Intervention: Lidocaine infiltration
Number of subjects: 144
Study: 29976305

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) management strategy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Coronary angiography management strategy
Number of subjects: 200
Study: 27373720

Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Hybrid procedure
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Totally minimally invasive surgery
Number of subjects: 104

Group type: COMPARATOR
Intervention: Recruitment rate
Number of subjects: 104

Group type: COMPARATOR
Intervention: Pain assessment
Number of subjects: 104

Group type: COMPARATOR
Intervention: Patient-reported outcomes
Number of subjects: 104

Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 104

Group type: COMPARATOR
Intervention: Length of stay
Number of subjects: 104
Study: 24192751

Group type: EXPERIMENTAL
Intervention: 750 mg telaprevir (TVR) at 8 h intervals
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 750 mg telaprevir (TVR) at 12 h intervals
Number of subjects: 52
Study: 22251974

Group type: COMPARATOR
Intervention: Cervical Laminectomy and Fusion (CLF)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Expansile Cervical Laminoplasty (ECL)
Number of subjects: 16
Study: 19081706

Group type: EXPERIMENTAL
Intervention: Human growth hormone (0.1 mg . kg(‐1) . d(‐1))
Number of subjects: 21

Group type: COMPARATOR
Intervention: Subcutaneous placebo
Number of subjects: 21
Study: 17225037

Group type: EXPERIMENTAL
Intervention: Therapy by therapists
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Daily therapy by more than one therapist
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Occupational therapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Speech pathology
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Upper-limb therapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Presence of family members during therapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Muscle weakness and left hemiparesis
Number of subjects: 58
Study: 16360523

Group type: EXPERIMENTAL
Intervention: Traditional surgical technique (submucosal resection)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Radiofrequency volumetric tissue reduction (RFVTR)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 225
Study: 12482192

Group type: EXPERIMENTAL
Intervention: 4 doses of the HiB vaccine (PPR‐D, Connaught) starting at 3 months of life
Number of subjects: 116000

Group type: COMPARATOR
Intervention: 0 doses of the HiB vaccine (control group)
Number of subjects: 116000
Study: 9935122

Group type: EXPERIMENTAL
Intervention: Dexamethasone 9 mg daily for 15 days, followed by a stepwise decrease in dosage, plus 300 IU of hMG daily for 10 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo, plus 300 IU of hMG daily for 10 days
Number of subjects: 36
Study: 7769049

Group type: EXPERIMENTAL
Intervention: ICI 182780, 12 mg/day i.m. for 7 days (n = 19)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (control group, n = 11)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ICI 182780
Number of subjects: 30
Study: 2180233

Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza B live attenuated intranasal vaccine (maximum potency, 1:2 dilution, titre of 10(7.0) EID50)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza B live attenuated intranasal vaccine
Number of subjects: 0
Study: 476709

Group type: EXPERIMENTAL
Intervention: methyl-CCNU and beta-2'-deoxythioguanosine
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: DGA
Number of subjects: 108

Group type: COMPARATOR
Intervention: VP-16-213
Number of subjects: 108

Group type: COMPARATOR
Intervention: Previous chemotherapy with nitrosourea
Number of subjects: 108
Study: 31757354

Group type: EXPERIMENTAL
Intervention: Cocaine users
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Cocaine users with negative drug screen
Number of subjects: 88
Study: 30583957

Group type: EXPERIMENTAL
Intervention: Clinical decision support providing patient-level clinically important traumatic brain injury risk estimates and management recommendations
Number of subjects: 3859

Group type: EXPERIMENTAL
Intervention: Clinical decision support
Number of subjects: 3859

Group type: COMPARATOR
Intervention: Control group (no clinical decision support)
Number of subjects: 3859
Study: 29228934

Group type: EXPERIMENTAL
Intervention: Mobile application simulator (MAS)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Traditional revision resources
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: No formal revision resources
Number of subjects: 27
Study: 26528654

Group type: EXPERIMENTAL
Intervention: Cognitive reactivity measured by the Leiden Index of Depression Sensitivity (LEIDS)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Rumination (a component of cognitive reactivity)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Dysfunctional cognitions measured by the Dysfunctional Attitudes Scale
Number of subjects: 116
Study: 23403877

Group type: EXPERIMENTAL
Intervention: Cluster 2 (non-core foods)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Cluster 1 (dietary guidelines)
Number of subjects: 231
Study: 21500104

Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 0
Study: 19285833

Group type: EXPERIMENTAL
Intervention: Bamboo shoot diet (360 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diet containing 25 g of cellulose
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dietary fiber-free diet (control)
Number of subjects: 8
Study: 17530960

Group type: EXPERIMENTAL
Intervention: Sprint Group (SG)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Plyometric Group (PG)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 93
Study: 15068645

Group type: EXPERIMENTAL
Intervention: Teledermatology
Number of subjects: 36
Study: 11463772

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg) alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bromocriptine after domperidone (20 mg) pretreatment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 10
Study: 9879155

Group type: EXPERIMENTAL
Intervention: Metrodin intramuscularly
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metrodin HP subcutaneously
Number of subjects: 20
Study: 1431192

Group type: EXPERIMENTAL
Intervention: Rowatinex
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 3893509

Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) 400 micrograms daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (prednisolone)
Number of subjects: 26
Study: 31028038

Group type: EXPERIMENTAL
Intervention: MH-COPD intervention group (n=50 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care control group (UC-COPD) (n=50 patients)
Number of subjects: 100